Cervical cancer rates are on the rise among younger women, owing in part to a lack of screening and prevention.

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Among women aged 20 to 24 years who were screened for cervical cancer, rates decreased by 79, 80 percent for CIN2+, CIN3+.

The authors highlight that cervical cancer accounts for 2% of new cancer cases in women in the UK, affecting over 3,000 people each year, with those from more socioeconomically deprived areas ...

After a patient has undergone treatment for cancer, they may be told that the disease is either in "remission" or that they have been "cured." But there's a distinction between these terms.

School of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin, P. R.

For the first time in history, four of Australia’s leading health organisations have joined forces with the Australian Government to ensure no one is left behind as Australia works towards eliminating ...

Researchers at the Institute of Technology, University of Tartu, present a robotics concept in which temporary robot embodiments and movement pathways are spun in situ from a polymer solution. They ...

In a small auditorium at the Princess Margaret Cancer Centre in Toronto, about a half-dozen cancer patients sit, getting tips on how to deal with hair loss during chemotherapy. It's not an unusual ...

grades 2 to 3 and adenocarcinoma in situ (AIS; collectively CIN2+) and CIN3+ (CIN grade 3 and AIS) among women aged 20 to 24 years who were screened for cervical cancer, according to research ...